It is no secret that cancer remains a global epidemic. According to The National Cancer Institute (http://dtn.fm/RK8lF), cancer is still one of the leading causes of death in the world, with more than 8.2 million cancer-related deaths back in 2012. The American Cancer Society (http://dtn.fm/RK8lF) estimates that in 2017, just in the U.S., there will be over 1.6 million new cancer cases, with more than 600,000 cancer-related deaths, and the number of new cancer cases is expected to rise to 22 million within the next 20 years.
Some of the most common types of cancer expected in 2017 include breast cancer, lung and bronchus cancer, prostate cancer, colorectal cancer, melanoma of the skin, and urinary bladder cancer, with lung and bronchus cancer expected to be the biggest killers. Each of the types of cancer listed above needs to be detected early in order for patients to have the best survival rates, something made possible only with effective cancer screening tests.
ITUS Corporation (NASDAQ: ITUS), a company in the business of developing a series of non-invasive, inexpensive blood tests in order to detect cancer early on, has come up with Cchek™, a new form of cancer screening test that has proven to be more accurate, reliable, easy, and affordable than current screening tests. Cchek™ is a diagnostic platform that focuses on a subset of cells that are said to appear at the beginning of the formation of a tumor. By using proprietary protocols and fluorescently labeled antibodies, Cchek™ counts and sorts the specific and rare cells.
Currently, Cchek™ has been validated with 14 cancer types and has tested 315 patients, with 225 testing positive for cancer and 87 testing negative. In the preliminary results, the company achieved sensitivity and specificity of 92% accordingly for 88 patient samples, including 54 samples from patients with a variety of types of cancer, and 34 healthy patients. Sensitivity and specificity are two scientific measurements that are used to establish the efficacy of a diagnostic test.
ITUS Corporation is in the process of submitting its data at scientific meetings and plans to publish its data shortly. The company is continuing to process new patient samples with the aim of testing new cancer types while evaluating benign conditions. Currently, ITUS is still undertaking double-blinded testing in order to take Cchek™ to the U.S. Food and Drug Administration (FDA) for future approval.
For more information, visit www.ITUSCorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment